Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying

FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad.In case you missed it: We are bringing one of our most critical recent conversations to unpack how regulatory uncertainty is shifting the future of medicine. FDA instability is reshaping biotech investment decisions in real time. Across the board, investors are recalibrating risk, pulling back on funding, and even shifting capital abroad.In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health to unpack new, original research conducted with investors across the biotech ecosystem. The goal was simple: move beyond speculation and understand whether recent leadership changes, staffing cuts, and policy uncertainty at the FDA are actually dictating investor behavior.The signal is clear. Across venture capital, public equity, private equity, and industry investors, the vast majority agree that recent changes at the FDA have fundamentally altered how they allocate capital and view the attractiveness of U.S.-based drug development.This Episode Covers Four Major Themes:🔹 Regulatory Instability: Growing investor concern over shifting FDA standards.🔹 Shifting Portfolios: A reduced appetite for funding complex product categories like gene therapy and vaccines.🔹 Global Competition: Increasing attention and capital flowing toward China and other international markets.🔹 The Innovation Pipeline: Broader fears that instability across agencies like the NIH and FDA will weaken long-term medical breakthroughs.At the center of it all is one core issue: regulatory predictability. When investors lose confidence in policy clarity and institutional knowledge, the consequences extend far beyond individual companies—they dictate where innovation happens next.Even with these concerns, investors still want to back innovation in the United States. The question is whether policymakers and regulators can restore the stability and trust that made the U.S. the global leader in biotech in the first place.Watch for a grounded conversation on what investors are really saying, what it means for the biotech ecosystem, and why FDA predictability matters more than ever. Check out the full report https://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investmentJoin the Conversation ⬇️Do you think FDA instability is already changing the future of biotech investment?Are investors right to look abroad when U.S. regulatory signals become less predictable?What matters more right now: speed, stability, or scientific consistency?Drop your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:X: https://x.com/MakingMedPodInstagram: https://www.instagram.com/makingmedicinepod/TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=enLinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true👍 Like and subscribe for more biotech and healthcare policy coverage.Time Stamps00:00 Intro & Disclaimer00:16 Investors Say FDA Changes Are Impacting Decisions03:22 How We Surveyed Investors (Research Design)07:27 Theme 1: FDA Instability & Investor Uncertainty10:22 Investors Repricing Risk in Biotech12:05 “Chaos Is the Only Thing” – Investor Quote13:00 Theme 2: Pullback from Gene Therapy, Vaccines, Oncology14:28 Theme 3: Capital Shifting Abroad (China & Competition)17:02 Theme 4: NIH Cuts & Long-Term Innovation Risk25:24 Key Takeaway: Regulatory Predictability Drives InvestmentDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#Biotech #FDA #BiotechInvesting #HealthcarePolicy #DrugDevelopment #makingmedicine